• Sporanox Capsule Contains
    Itraconazole 100mg

Sporanox Capsules 100mg

Sporanox is a systemic broad-spectrum antifungal agent available in capsule form for oral administration.

How Sporanox Works?

As with all azole antifungal agents, Sporanox works principally by inhibition of cytochrome P450 14a-demethylase (P45014DM). A major consequence of this interaction is disruption of intracellular membrane and defective formation of the fungal cell membrane with inhibition of lanosterol demethylase leading to accumulation of membrane precursor lipids such as lanosterol.

What is Sporanox Used For? > Indications

Sporanox is primarily used for the treatment of;

  • Dermatophytosis
  • Superficial candidiasis
  • Pityriasis versicolor
  • Oculomycoses
  • Subcutaneous mycoses
  • Systemic mycoses
  • Antifungal prophylaxis
  • Other infections

Recommended Dosage of Sporanox Capsules

Various dosage regimes have been found successful; typical doses Sporanox Capsules are listed below.

Courses can be repeated and the treatment with Sporanox can be continued for months if necessary
  • Tinea corporis, Tinea cruris
    200mg daily for one week OR 100mg daily for 2 weeks
  • Tinea pedis, Tinea manuum
    200mg twice daily for one week OR 100mg daily for 2-4 weeks
  • Vulvovaginal candidiasis
    200mg twice daily for one day OR 200mg daily for 3 days
  • Oral candidiasis
    100mg daily for 2 weeks
  • Tinea unguium
    200mg/day for 6-8 weeks (Fingernails) OR 3-4 months (Toenails)
    200mg twice daily for 7 days, repeated monthly for 2months (Fingernails) OR 3-4 months (Toenails)
  • Blastomycosis and histoplasmosis
    The recommended dose is 200mg once daily
  • Aspergillosis
    A daily dose of 2 to 4 capsules of Sporanox is recommended

The dose of Sporanox in children is usually 5mg per kg body weight per day to maximum 200mg per day but is reserved for exceptional circumstances OR As directed by the physician.

Possible Side Effects of Sporanox

Sporanox appears to be a relatively safe drug. Side effects of Sporanox (usually minor) are more likely during a prolonged course of treatment. Cases of nausea and vomiting, constipation, headache and dizziness are observed. Abnormal liver function tests are also observed in patients with long-term therapy. Urticaria, endocrine effects including enlarged breasts (In males) and adrenal suppression, tingling in the fingers and toes (Very rare) and congestive heart failure were also observed rarely.

Sporanox should not be taken during pregnancy. Although only excreted in tiny amounts from breast milk, a lactating mother should only take it, if it is really essential.

Sporanox Overdose

There are no reports of over-dosage. In the event of accidental over-dosage, supportive measures should be employed. Within the first hour after ingestion, gastric lavage may be performed.

Activated charcoal may be given if considered appropriate. Sporanox cannot be removed by hemodialysis.

Pharmacokinetic Properties of Sporanox

Sporanox is well absorbed when given by mouth after a full meal. Mean peak plasma concentrations can be reached within 3 to 4 hours and for a 100mg dose, can range from 400 to 600mg per ml at steady state, which can be reached within 1 to 2 weeks.

Bioavailability increases with doses of 100 to 400mg in such a manner as to suggest that Sporanox undergoes saturable metabolism. Sporanox is highly protein bound; only 0.2% circulates as free drug. Concentrations of Sporanox in whole blood are 60% of those in plasma. Sporanox is widely distributed but only small amounts diffuse into the CSF. Therapeutic concentration of Sporanox remains in the skin and mucous membranes for 1 to 4 weeks after the drug is discontinued. Sporanox is metabolized in liver to inactive compounds, which are excreted in the bile or urine, 3 to 18% is excreted through feces as unchanged drug.

Renal excretion of the parent drug is less than 0.03% of the dose. About 35% of a dose is excreted as metabolites in the urine within 1 week. The half-life of Sporanox is reported as 20 hours, increases to 30 hours with continued administration. Elimination from plasma is biphasic with a terminal half-life of 1 to 1.5 days.

Therapeutic levels in vaginal tissues are maintained for another 2 days after discontinuation of the 3 days course with 2 Capsules of Sporanox daily and for another 3 days after discontinuation of a 1 day course with 2 Capsules bd.